SCHEMBL2643693

SCHEMBL2643693

CC(Oc1cc(C(=O)O)cc2c1CC(C)(C)O2)c1ccncn1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 2/20 0.36
IRAK4 Q9NWZ3 2/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 3/20 0.33
GLA P06280 2/20 0.33
HPGD P15428 2/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GCK P35557 1/20 0.32
RCE1 Q9Y256 1/20 0.31
CCR8 P51685 1/20 0.31
KCNH2 Q12809 1/20 0.31
NOD1 Q9Y239 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
HPGDS O60760 1/20 0.31
KMO O15229 1/20 0.30
VNN1 O95497 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644675 0.87 KMO (0.41) NOX1KCNH2KMO
SCHEMBL2644362 0.85 IRAK4 (0.33) IRAK4KDM4EALDH1A1GAAGLA
SCHEMBL2643467 0.84 KMO (0.40) IRAK4KDM4EALDH1A1GAAGLA
SCHEMBL644403 0.82 GCK (0.54) NOX1IRAK4GCKKCNH2
SCHEMBL2644051 0.81 KDM4E (0.32) IRAK4KDM4EALDH1A1GAAGLA
SCHEMBL2644681 0.75 GCK (0.39) NOX1KDM4EALDH1A1GAAGLA
SCHEMBL2644915 0.73 GCK (0.36) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2643933 0.72 TSHR (0.43) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2645432 0.71 LDHA (0.40) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2644528 0.71 ALDH1A1 (0.37) KDM4EALDH1A1GAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 NOX1 805/4885IRAK4 1227/4885KDM4E 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.